Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of galicaftor + navocaftor with or without ABBV-119 in cystic fibrosis with F508del mutation
NL-OMON49886Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of galicaftor, navocaftor and ABBV-119 in cystic fibrosis (CF) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Absolute change from baseline in percent predicted forced expiratory volume in 1 second. Started Oct 2021; status: completed.
02
Drugs
galicaftornavocaftorABBV-119
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON49886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49886.